Holen Sie sich die Stockscreener-App
1.46
13.18%
0.17
Handel nachbörslich:
1.47
0.01
+0.68%
Scienture Holdings Inc Aktie (SCNX) Neueste Nachrichten
Scienture Holdings terminates equity line of credit ahead of product launch - Investing.com
Scienture Holdings Announces Cancelation of ELOC | SCNX Stock Ne - GuruFocus
Scienture Holdings Announces Cancelation of ELOC - The Manila Times
Scienture Holdings Announces Cancelation of ELOC | SCNX Stock News - GuruFocus
Scienture Holdings, Inc. Terminates Equity Line of Credit to Focus on Launching FDA-Approved Arbli - Nasdaq
Scienture Terminates $310M Credit Line to Focus on Revolutionary Liquid Hypertension Drug Launch - Stock Titan
Scienture appoints Hariharan, Mani as co-CEOs - MSN
SCIENTURE Appoint Dr. Shankar Hariharan and Dr. Narasimhan Mani as Co-CEO’s - citybiz
Scienture Appoints Co-CEOs as Suren Ajjarapu Steps Down - marketscreener.com
SCIENTURE Announces Executive Leadership Transition | SCNX Stock News - GuruFocus
SCIENTURE Announces Executive Leadership Transition - The Manila Times
Scienture Holdings, Inc. Announces Leadership Transition as Suren Ajjarapu Steps Down as CEO and Chairman - Nasdaq
Scienture Names Two Pharma Veterans as Co-CEOs in Strategic Leadership Overhaul - Stock Titan
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, - GuruFocus
Scienture Holdings, Inc. Announces FDA Patent Listing for Arbli™, First FDA-Approved Liquid Losartan Formulation - Nasdaq
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. - The Manila Times
FDA Orange Book Milestone: First-Ever Liquid Losartan Secures Patent Protection Until 2041 - Stock Titan
Long-Term Bull Put Spread Provides Opportunities for ARM Bulls - The Globe and Mail
ON Holding Surges, Leads High-End Retailers Into Reversal - The Globe and Mail
Scienture Holdings: Q1 Earnings Snapshot - CTPost
Scienture Holdings, Inc. SEC 10-Q Report - TradingView
Why Rigetti Computing Stock Soared in April - The Globe and Mail
3 Consumer Discretionary Stocks to Buy in a Divided Economy - The Globe and Mail
Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025 - marketscreener.com
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - The Manila Times
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. | SCNX Stock News - GuruFocus
Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - Stock Titan
Scienture Holdings Divests Subsidiaries to Tollo Health - MSN
Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa
Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - marketscreener.com
Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener
Scienture Holdings divests subsidiaries for $5 million - Investing.com
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times
Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan
SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa
Scienture Holdings gears up for specialty pharma launches - Investing.com
Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks
Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK
Scienture Holdings, Inc. Issues Annual Letter to Shareholders - TradingView
Investors: What’s The Real Deal With Scienture Holdings Inc (NASDAQ: SCNX) - Stocks Register
Scienture Holdings Inc. (SCNX) reports earnings - Quartz
Scienture Bolsters Commercial Operations with New Leadership and Syneos Health Partnership - AInvest
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - The Manila Times
Scienture Gears Up for Major Product Launch: New CCO and Syneos Health Partnership Signal Growth - Stock Titan
3 Reasons APG is Risky and 1 Stock to Buy Instead - The Globe and Mail
Scienture Holdings Announces FDA Approval for ArbliTM - TipRanks
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Scienture Holdings announces draw on Equity Line of Credit - MSN
Scienture announces draaw on Equity Line of Credit - TipRanks
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Manila Times
3.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):